I just returned from a conference called the NASH Summit. It is a gathering of about 200 of the top liver researchers and scientists in the world. Small but very much cutting edge. I must say that as a cirrhosis patient I am so encouraged, perhaps verging on rapture, at the progress being made to develop treatments for liver disease. (I'll get some guff for that kind of language but understand that as patients we know there is no medical help for us today)
I go to these meetings and I am always so encouraged by what I see there. This was the first conference where we have presented a poster of our progress which was fun. We usually are audience not part of the show. Here is a link if you would like to see it.
This was our first real opportunity to announce that Intercept has awarded us a grant to begin the first phase of our screening program aimed at finding people with liver disease before they have symptoms. Here is a link to information about that plan.
All good. Indeed, but coming back to the "real" world is kind of like a hangover. The problem is that the drug trials that are required for treatments to be proven can't happen in the world as it exists today. Even though liver disease is epidemic and threatens the lives of millions of people no one knows who they are. The number of active patients who can be considered for participation in a clinical trial is tiny compared to the need. So as someone who appreciates research I am so pleased, but as a patient I know that any treatment will be delayed by years because of the clinical trial problem. I try not to be angry about it though I fail at times.
The problem is that even though we know that there are millions of people who are slowly killing their livers, because it rarely has symptoms, we wait until it becomes a life threatening issue to act. It is standard practice not to screen for liver disease even when we know statistically that someone is in danger. When we didn't have the ability to screen that made sense, but now we do and that gets my goat. It is what led to our championing of our screening program but we will need a lot of help to make a difference in any reasonable time frame. Maybe we'll get it so stay tuned.
One quick example from the conference to show you just how bad it is. Research has shown that up to 70% of people with type 2 diabetes have undiagnosed liver disease. That is a shocking number since there are around 30 million of those folks. A company that does clinical trials reported that they had 35,000 patients in their database. They asked how many had diabetes and it was 18,000. So how many also had a diagnosis of NASH. What would you guess that number would be? Thousands surely given what we know of the disease. The answer 219. TWO HUNDRED NINETEEN!!!!! I knew it was a bad situation but that really depressed me. That is the real world today. A very large amount of disease cooking along and no effective outreach so no timely clinical trials and death by end stage liver disease. Interesting statistically unless you happen to get on the wrong side of the line.
Enough for now. Split brain doesn't help. I'm headed to Houston this week which is where we plan to put our pilot screening center so baby steps for now. I'll let you know how it goes.
An ironic curse with the clear implication that 'uninteresting times', of peace and tranquillity, are more life-enhancing than interesting ones. Another cautionary message is 'be careful what you wish for', and yet another 'fools rush in where wise men never go'.
Cliche man is here apparently, but the old warnings aren't necessarily wrong. I want to let you know that the foundation has entered an 'interesting time'
We have been greatly honored with support and now it is time for us to stop talking and start dancing. Intercept Pharmaceuticals has agreed to provide the first funding for our screening program and we plan to open our first pilot facility in Houston in the summer. For those who have joined us recently, we advocate building 400 screening centers across the US and to screen 1 million people a year who are at risk for liver disease from the large co-morbid (people with multiple diseases) population.
We have also been invited to present a poster at the 2018 NASH-Summit later this month. This is a gathering of world leaders in liver disease research. At conferences like this industry leaders present their latest results and give talks about where things are headed but they also have an area where promising results can be presented in poster form. Sort of like being the warm up act for the Beatles. This will be our first experience presenting a poster so that will be 'interesting" but it is an honor. Space is always limited and there are thousands of people working in the field so we were pleased to be included.
We have formed a partnership with HealthUnlocked to provide the digital platform for our online community called
Check it out. The thing that sets this apart as a patient tool compared to platforms like FaceBook is that it is ad free. We do not flood you with constant junk that just wastes your time. If you are in a forum you are likely ill and don't need to have your life energy sucked at by marketing pukes. Some day I'll tell you how I feel about that.
In association with Intercept we are also producing some patient videos and a media campaign to help educate people about liver disease and things they need to know about the system. A major problem in society is that people just don't understand liver disease, its causes, consequences, or management. A central mission of the foundation is to try to improve that.
We hope you are well. If you think others might be interested in any of this please feel free to forward this, and if you like what we are doing any financial support you can send along will be greatly appreciate.
When I think about screening for liver disease I often find that tune from My Fair Lady, "Why Can't A Woman Be More Like A Man" running through my mind.
It is an odd mental tick I suppose. One of my favorite musicals connecting to a potentially terminal illness, but the challenge we face as liver patients would largely vanish if only a liver was more like a breast.
OK, I stretch the analogy a bit here but consider how cancer is managed. We search diligently for cancer and while there are significant differences between cirrhosis and breast cancer the statistics are interesting. There are around 40,000 deaths annually from each disease, but we search out the tiniest incidence of breast cancer that we can find and manage it aggressively but we ignore liver disease until it presents serious symptoms. Think about that for just a moment. Why would we test breasts regularly but intentionally ignore early liver disease?
The answer is that we don't have any pills and the treatment is dietary and lifestyle counseling which we suck at and have largely failed to do well. We see that from the obesity challenges our society is facing. Beyond that, historically we didn't have any useful and inexpensive tests to really measure the disease. Plenty of ways to explain the past, but today we do understand the bio-chemisty better and we do have ways to test for disease that hasn't caused symptoms yet.
One might think that we would be rushing forward with screening but we aren't. Among the reasons are that insurance doesn't really want to pay for wellness testing and it isn't the business model for medicine. There are efforts to change to a wellness model but what we have is a very entrenched system. We also still are faced with the fact that the best we have to offer is advice about how to eat better and the diet industry is a great example of a failure as people routinely yoyo up and down with their weight.
The Foundation believes that we should be screening the at risk liver population now and working on education about food because in the long run that will still be the best therapy even after they develop expensive pills. To that end we are sponsoring a screening project designed to make low cost testing available and to provide early warning to people before they become ill. If the subject is of interest here is a link to it.
If you like what we are doing tell your friends to sign up for our newsletter
We Advocate Early Screening
- Overview of the project and proposed funding model
- The purpose is to develop the operating funding for the initial phase of the Fatty Liver Screening Project
- The key value to industry participants is that a key goal of the project is to identify a large number of asymptomatic and undiagnosed patients who have fibrotic liver disease and have been educated about clinical trial participation.
If you think about the co-morbidity illustrated in this image, it is clear that there are at least 40 million Americans who are at some level of risk for developing advanced disease. The question, "WHAT TO DO" hangs there in the face of vast suffering to come.
Studies are coming in as research focuses on liver disease and the challenges that we face. A whole body view instead of organ by organ is becoming more common which recognizes that the liver is so foundational to health that a very wide range of diseases are co-morbid with liver disease. That is a fancy word that means the problems are related.
A good example is diabetes. The high degree of co-morbidity of NASH and diabetes is well known and up to 70% of T2D patients have undiagnosed liver disease. There is a lot of data about the co-morbid nature of liver disease. It may be fair to ask how it is possible for 70% of the diabetes patients to have undiagnosed liver disease, but it is simply due to the fact that absent complications it isn't looked for. If you want to look at the research, here are a couple of links
It is important to understand that this is related to the standards of care published for the profession and is based upon the fact that there hasn't been enough testing to validate the use of existing tools in a screening mode. If you are interested in reading the guidelines, here is a link to the current document.
Since the policy is that we probably should screen but can't prove it, what is the next step? It is a classical thought experiment, might it not be better to intercept that disease process before it becomes a fully co-morbid problem? The question then is can it be done? Recent studies by several researchers have shown that Fibroscan is about as effective as MRE in identifying fibrosis at late stage 2 and higher as reported in the material above and is much cheaper.
If we take the result of our thought experiment to be that we can and should divert patients prior to illness, how do we do that? We know that diet is fundamental and it is generally recommended that people eat a plant based diet. A recent review of available studies is of value as it summarizes what we know at this time. Here is a link to an excellent review of current thinking.
We recommend a substantial surplus of oleic acid as the dietary fat associated with a plant based diet. The study by George ET AL outlines the current situation well, but our view of dietary fats goes beyond these guidelines and recommends that the predominate fat should be oleic acid from extra virgin olive oil. We believe our view is supported by this research among others, but confer with your doctor before making dietary changes as we are patients not doctors.
The use of oleic acid yields the most efficient energy production at the mitochondria and is foundational to a healing diet. As a review, here is a link to our diet recommendations.
The solution to the problem posed by the standards of care guidelines is to do the work required to satisfy the standards committee that screening really is worthwhile and it is the mission of the Foundation to carry out this screening study in order to intercept people who are unknowingly developing liver disease and divert them to care through early screening so that they may not develop life threatening illness. For more information, here is a link to an overview of the project.
We anticipate beginning the initial trials this year so please stay tuned. If you appreciate the work we are doing consider contributing to our effort. All donations are tax deductible as we are a 501(c)(3) qualified non-profit foundation.
Non Alcoholic Steatohepatitis (NASH) is a type of fatty liver disease, characterized by inflammation of the liver with concurrent fat accumulation in liver. Mere deposition of fat in the liver is termed steatosis, and together these constitute fatty liver changes.
There are two main types of fatty liver disease: alcohol-related fatty liver disease and non-alcoholic fatty liver disease (NAFLD). Risk factors for NAFLD include diabetes, obesity and metabolic syndrome. When inflammation is present it is referred to as alcoholic steatohepatitis and nonalcoholic steatohepatitis (NASH). Steatohepatitis of either cause may progress to cirrhosis, and NASH is now believed to be a frequent cause of unexplained cirrhosis (at least in Western societies). NASH is also associated with lysosomal acid lipase deficiency.
This video is fairly technical, but well worth the time to watch. Dr. Stephen Harrison, Hepatologist and international opinion leader in fatty liver disease and NASH, discusses the evolving landscape of fatty liver disease in the United States as well as diagnostic approaches to identify patients at risk for this disease.